Celiac disease medical therapy

Jump to navigation Jump to search

Celiac disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Celiac disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modifications
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Celiac disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Celiac disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Celiac disease medical therapy

CDC on Celiac disease medical therapy

Celiac disease medical therapy in the news

Blogs onCeliac disease medical therapy

Directions to Hospitals Treating Celiac disease

Risk calculators and risk factors for Celiac disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
  • Pharmacologic medical therapies for celiac disease include gluten-free diet.[1][2]
  • Patient should be referred to a dietitian once the diagnosis of celiac disease is made.
  • Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Celiac Disease

  • Dietary modification
    • 1.1 Gluten-free diet (GFD)
      • 1.1.1 Storage protein not allowed
        • Wheat
        • Rye
        • Barley,
        • Spelt
        • Kamut
        • Emmer wheat
        • Einkorn wheat
        • Green spelt
      • 1.1.2 Storage protein allowed
        • 1.1.2.1 Comparatively more nutritious (more nutritious than other starches in the Gluten free diet; higher fiber, protein, calcium, iron.)
          • Amaranth
          • Buckwheat
          • Legumes
          • Quinoa
          • Sorghum/Milo
          • Soy
          • Tef/Teff
        • 1.1.2.2 Comparatively less nutritious
          • Arrowroot
          • Corn/maize
          • Indian Rice Grass (Montina)
          • Mesquite
          • Millet
          • Nuts
          • Potato
          • Rice
          • Tapioca
          • Wild rice
          • Pure oats (oats that are not contaminated by gluten)[3]
          • Wheat starch
          Note: The is evidence that wheat starch is a safe and well-tolerated addition to gluten-free diet.However, wheat starch is not currently accepted in the United States or Canadian GFD.
    • 2.1 Nutritional supplements (must be strict gluten-free)
      • Fiber
      • Iron
      • Calcium
      • Vitamin D
      • Magnesium
      • Zinc
      • Vitamin B complex (folate, niacin, vitamin B12, riboflavin)
      Note: Even while on a diet, health-related quality of life (HRQOL) may be decreased in people with coeliac disease. Some have persisting digestive symptoms or dermatitis herpetiformis, mouth ulcers, osteoporosis and fractures. Symptoms suggestive of irritable bowel syndrome may be present, and there is an increased rate of anxiety, fatigue, dyspepsia and musculoskeletal pain.[4]

Refractory disease

A tiny minority of patients suffer from refractory disease, which means they do not improve on a gluten-free diet. This may be because the disease has been present for so long that the intestines are no longer able to heal on diet alone, or because the patient is not adhering to the diet, or because the patient is consuming foods that are inadvertently contaminated with gluten. If alternative causes have been eliminated, steroids or immunosuppressants (such as azathioprine) may be considered in this scenario.

References

  1. Schuppan D, Zimmer KP (2013). "The diagnosis and treatment of celiac disease". Dtsch Arztebl Int. 110 (49): 835–46. doi:10.3238/arztebl.2013.0835. PMC 3884535. PMID 24355936.
  2. Kupper C (2005). "Dietary guidelines and implementation for celiac disease". Gastroenterology. 128 (4 Suppl 1): S121–7. PMID 15825119.
  3. Rashid M, Butzner D, Burrows V, Zarkadas M, Case S, Molloy M, Warren R, Pulido O, Switzer C (2007). "Consumption of pure oats by individuals with celiac disease: a position statement by the Canadian Celiac Association". Can. J. Gastroenterol. 21 (10): 649–51. PMC 2658132. PMID 17948135.
  4. Häuser W, Gold J, Stein J, Caspary WF, Stallmach A (2006). "Health-related quality of life in adult coeliac disease in Germany: results of a national survey". Eur J Gastroenterol Hepatol. 18 (7): 747–54. doi:10.1097/01.meg.0000221855.19201.e8. PMID 16772832.

Template:WH Template:WS